For decades, selective serotonin reuptake inhibitors (SSRIs) have been among the most commonly prescribed medications for depression and anxiety disorders [1–3]. Drugs such as fluoxetine, sertraline, escitalopram, and citalopram have helped millions of people manage symptoms and improve their quality of life.
Despite their widespread use, many people still believe that SSRIs work by simply correcting a “chemical imbalance” in the brain — specifically, a deficiency of the neurotransmitter serotonin [4,5]. This explanation has been repeated in media reports, advertisements, and even some healthcare settings for years. However, modern neuroscience suggests that the reality is far more complex and nuanced.
Today, many researchers view depression not as a straightforward serotonin deficiency but as a multifaceted condition involving changes in brain circuitry, stress responses, inflammation, neuroplasticity, and multiple neurotransmitter systems. SSRIs appear to influence these broader biological processes, which may explain why their benefits often take weeks to emerge, despite increasing serotonin levels within hours. This article will examine how SSRIs actually work beyond the context of this early framework of understanding.
The Origins of the Serotonin Hypothesis
The serotonin hypothesis emerged in the 1960s after researchers observed that certain antidepressants influenced serotonin signaling [6]. Serotonin is a neurotransmitter involved in mood regulation, sleep, appetite, memory, learning, and emotional processing.
Scientists discovered that antidepressant drugs could increase serotonin availability in the brain, leading to the idea that depression might result from a deficiency of serotonin. This concept gained traction because it offered a relatively simple biological explanation for an admittedly complex condition.
However, over time, researchers began noticing inconsistencies. For example, many people with depression do not show obvious serotonin deficiencies, and lowering serotonin in experiments does not reliably induce depression in healthy individuals [4]. Furthermore, SSRIs increase serotonin levels within hours, yet symptom improvement often takes several weeks to manifest. These findings indicate that serotonin may be involved in depression, but not in the simplistic way it was initially proposed.
How Do SSRIs Affect Serotonin?
Neurons communicate through chemical messengers called neurotransmitters. After serotonin is released into the synapse (the space between neurons), it is normally reabsorbed by the serotonin transporter (SERT). SSRIs block this transporter, preventing serotonin from being recycled as quickly. As a result, serotonin remains in the synapse longer and can continue interacting with serotonin receptors.
This effect occurs rapidly, often after the first dose. However, the immediate increase in serotonin does not fully explain the delayed therapeutic effects observed in depression treatment [7]. On the contrary, researchers now believe that the downstream changes triggered by prolonged SSRI use may be more important than the initial increase in serotonin itself.
Neuroplasticity: A Leading Modern Theory
One of the most influential theories is that SSRIs enhance neuroplasticity, the process by which the brain adapts, reorganizes, and forms new neural connections in response to experiences and environmental demands [8]. Healthy neuroplasticity allows the brain to learn, recover from stress, and adapt to changing circumstances.
Chronic stress and depression are associated with reduced neuroplasticity in key brain regions, including the hippocampus, prefrontal cortex, and the amygdala. These changes may contribute to persistent negative thought patterns, impaired emotional regulation, and reduced resilience.
Research suggests that SSRIs may gradually reverse some of these effects by promoting neuronal growth, strengthening synaptic connections, and enhancing the brain's capacity for adaptation [9–11]. Rather than simply increasing serotonin, SSRIs may help create conditions that allow healthier patterns of brain function to emerge over time.
A key player in the neuroplasticity theory is brain-derived neurotrophic factor (BDNF). BDNF is a protein that supports neuron survival, synaptic formation, learning and memory, as well as neural growth and repair.
Many studies have found reduced BDNF levels in people experiencing depression [12–14]. Importantly, chronic stress can suppress BDNF production, potentially contributing to structural and functional changes in the brain. Long-term SSRI treatment appears to increase BDNF expression in several brain regions, which may help restore neural flexibility and improve communication between brain networks involved in mood regulation.
Importantly, these neuroplastic changes develop gradually over weeks, mirroring the timeline of clinical improvement often seen with antidepressant treatment.
The Role of Inflammation
In recent years, inflammation has emerged as another important factor in depression research. A subset of individuals with depression shows elevated levels of inflammatory markers such as C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α).
Inflammation can influence neurotransmitter metabolism, stress responses, and neuroplasticity, potentially contributing towards depressive symptoms. Interestingly, some SSRIs appear to possess mild anti-inflammatory properties. Research suggests they may reduce certain inflammatory signaling pathways and modulate immune activity [15].
Although inflammation is unlikely to explain all cases of depression, it may represent an important piece of the puzzle for some individuals.
Why SSRIs Do Not Work for Everyone
If we accept that depression involves multiple biological systems, it becomes easier to understand why SSRIs are not universally effective.
Clinical studies consistently show that the antidepressant response varies substantially between individuals. Some people experience dramatic improvement, whereas others notice only modest benefits or none at all [16–20].
Several factors may influence treatment response, including genetics, the severity of depression, stress, inflammation status, brain network differences, coexisting medical conditions, and lifestyle factors. Also, because depression is biologically diverse, a treatment that helps one person may not work as well for another.
This recognition has fueled growing interest in personalized psychiatry, where treatments are tailored to an individual's unique biological and psychological characteristics.
Moving Beyond the “Chemical Imbalance” Narrative
In recent years, many experts have argued that the chemical imbalance explanation oversimplifies depression and the action of antidepressants. While serotonin remains important, depression cannot be reduced to a simple serotonin shortage, in the same way that diabetes involves insulin deficiency. Rather, depression appears to arise from complex interactions between neurotransmitters, brain circuitry, neuroplasticity, stress physiology, immune function, genetics, and environmental factors. SSRIs interact with many of these systems simultaneously, and their effects extend far beyond merely increasing serotonin concentrations in the synapse.
This more nuanced understanding does not mean that SSRIs are ineffective. Rather, it suggests they may operate through broader mechanisms that scientists are still working to fully unravel.
Conclusion
The idea that antidepressants “fix low serotonin” is increasingly viewed as an oversimplification of a much more complex biological reality. SSRIs do increase serotonin availability, but this is likely only the beginning of a cascade of changes occurring throughout the brain and body.
Modern research suggests that their therapeutic effects may stem from enhanced neuroplasticity, increased BDNF signaling, improved emotional processing, normalization of stress systems, changes in brain network connectivity, and even modulation of inflammation status.
Depression itself is now understood as a multifaceted disorder involving far more than a single neurotransmitter deficiency. As our scientific understanding evolves, so too does our appreciation of how antidepressants work - and why their effects vary among different people. Although many questions remain unanswered, one thing is increasingly clear: SSRIs do far more than simply boost serotonin. They appear to help the brain regain its capacity to adapt, learn, and recover from the biological effects of chronic stress and depression.
References
[1] C. Sanchez, E.H. Reines, S.A. Montgomery, A comparative review of escitalopram, paroxetine, and sertraline: are they all alike?, International Clinical Psychopharmacology 29 (2014) 185–196. https://doi.org/10.1097/YIC.
[2] P.J. Cowen, SSRIs in the Treatment of Depression: A Pharmacological CUL-DE-SAC?, in: M. Browning, P.J. Cowen, T. Sharp (Eds.), Emerging Neurobiology of Antidepressant Treatments, Springer International Publishing, Cham, 2023: pp. 1–19. https://doi.org/10.1007/7854_
[3] N.R. Marasine, S. Sankhi, R. Lamichhane, N.R. Marasini, N.B. Dangi, Use of Antidepressants among Patients Diagnosed with Depression: A Scoping Review, BioMed Research International 2021 (2021) 6699028. https://doi.org/10.1155/2021/
[4] J. Moncrieff, R.E. Cooper, T. Stockmann, S. Amendola, M.P. Hengartner, M.A. Horowitz, The serotonin theory of depression: a systematic umbrella review of the evidence, Mol Psychiatry (2022). https://doi.org/10.1038/
[5] B. Ang, M. Horowitz, J. Moncrieff, Is the chemical imbalance an ‘urban legend’? An exploration of the status of the serotonin theory of depression in the scientific literature, SSM - Mental Health 2 (2022) 100098. https://doi.org/10.1016/j.
[6] S. Bremshey, J. Groß, K. Renken, O.A. Masseck, The role of serotonin in depression—A historical roundup and future directions, Journal of Neurochemistry 168 (2024) 1751–1779. https://doi.org/10.1111/jnc.
[7] K.G. Commons, S.E. Linnros, Delayed Antidepressant Efficacy and the Desensitization Hypothesis, ACS Chem. Neurosci. 10 (2019) 3048–3052. https://doi.org/10.1021/
[8] C. Kraus, E. Castrén, S. Kasper, R. Lanzenberger, Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression, Neuroscience & Biobehavioral Reviews 77 (2017) 317–326. https://doi.org/10.1016/j.
[9] E. Segi-Nishida, The Effect of Serotonin-Targeting Antidepressants on Neurogenesis and Neuronal Maturation of the Hippocampus Mediated via 5-HT1A and 5-HT4 Receptors, Front. Cell. Neurosci. 11 (2017) 142. https://doi.org/10.3389/fncel.
[10] C. Anacker, P.A. Zunszain, A. Cattaneo, L.A. Carvalho, M.J. Garabedian, S. Thuret, J. Price, C.M. Pariante, Antidepressants increase human hippocampal neurogenesis by activating the glucocorticoid receptor, Mol Psychiatry 16 (2011) 738–750. https://doi.org/10.1038/mp.
[11] M.B. Reed, T. Vanicek, R. Seiger, M. Klöbl, B. Spurny, P. Handschuh, V. Ritter, J. Unterholzner, G.M. Godbersen, G. Gryglewski, C. Kraus, D. Winkler, A. Hahn, R. Lanzenberger, Neuroplastic effects of a selective serotonin reuptake inhibitor in relearning and retrieval, NeuroImage 236 (2021) 118039. https://doi.org/10.1016/j.
[12] A.S. Correia, A. Cardoso, N. Vale, BDNF Unveiled: Exploring Its Role in Major Depression Disorder Serotonergic Imbalance and Associated Stress Conditions, Pharmaceutics 15 (2023) 2081. https://doi.org/10.3390/
[13] Md.P.Z. Emon, R. Das, N.L. Nishuty, M.M.A. Shalahuddin Qusar, M.A. Bhuiyan, Md.R. Islam, Reduced serum BDNF levels are associated with the increased risk for developing MDD: a case–control study with or without antidepressant therapy, BMC Res Notes 13 (2020) 83. https://doi.org/10.1186/
[14] A.R. Brunoni, M. Lopes, F. Fregni, A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression, International Journal of Neuropsychopharmacology 11 (2008) 1169–1180. https://doi.org/10.1017/
[15] V. Dionisie, G.A. Filip, M.C. Manea, M. Manea, S. Riga, The anti-inflammatory role of SSRI and SNRI in the treatment of depression: a review of human and rodent research studies, Inflammopharmacol 29 (2021) 75–90. https://doi.org/10.1007/
[16] A.C.Y. Chan, Safety Concerns, Mechanistic Pathways, and Knowledge Gaps in the Clinical Use of Selective Serotonin Reuptake Inhibitors, Cureus (2026). https://doi.org/10.7759/
[17] G. Frazzetto, The drugs don’t work for everyone: Doubts about the efficacy of antidepressants renew debates over the medicalization of common distress, EMBO Rep 9 (2008) 605–608. https://doi.org/10.1038/embor.
[18] J. Moncrieff, Against the stream: Antidepressants are not antidepressants – an alternative approach to drug action and implications for the use of antidepressants, BJPsych Bull 42 (2018) 42–44. https://doi.org/10.1192/bjb.
[19] Al-harbi, Treatment-resistant depression: therapeutic trends, challenges, and future directions, PPA (2012) 369. https://doi.org/10.2147/PPA.
[20] A.M. Alqahtani, C. Kumarappan, V. Kumar, R. Srinivasan, V. Krishnaraju, Understanding the genetic aspects of resistance to antidepressants treatment, European Review for Medical and Pharmacological Sciences 24 (2020) 7784–7795. https://doi.org/10.26355/
